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1. Introduction
Shakespeare said that a rose by any other name would smell
as sweet. Analogously, obesity as a clinical entity based on its
current definition of a BMI>30Kg/m2 remains essentially the
same thing, whatever we name it. Unfortunately however, BMI
which is calculated from just two basic anthropometric mea-
surements, is seriously limited as a sole diagnostic criterion for
obesity. It is accepted that on a population-based epidemio-
logical level, BMI appears to perform well as a measure of
adiposity [1]. Although BMI usually also correlates well with
adiposity on an individual level, ‘excessive adiposity’ as a
concept seems quite subjective. Furthermore, BMI also corre-
lates with muscularity, and therefore stumbles as a definition
of obesity in some people with excessive muscularity. Finally,
‘excessive adiposity’ may occur at a BMI <30Kg/m2 in some
people with sarcopenia for example. BMI as an indicator of
‘excessive adiposity’ is therefore inherently flawed, particularly
in those people with abnormal body habitus. A further limita-
tion of BMI is that it provides no indication of body fat
distribution. It is well-established that fat distribution (such as
visceral versus subcutaneous gluteal fat) influences risk of
metabolic dysfunction and co-morbidity development [2].
Although waist circumference is a useful measure of visceral
fat, this measurement does not feature as a diagnostic criter-
ion for obesity based on its current definition.
With these diagnostic limitations in mind, there are three
main arguments to discuss when considering whether obesity
should be classified as a disease.
2. The ‘collective acceptance’ argument
‘Collective acceptance’ is used here to define a scenario whereby
a group, population or nation shares collectively in a particular
belief without question. An example herewould be the value of a
£5 note. Humans seem to have great ability to share collective
beliefs, evenwhen this belief provokes cognitive dissonance. The
American Medical Association labelled obesity as a disease in
2013 [3], and this move was followed by other esteemed socie-
ties. Such conformity has set the stage for collective acceptance
within themedical community, that obesity should be labelled as
a disease.
The collective acceptance perspective is, perhaps less of an
argument for obesity being a disease, as an explanation for
prevailing view-points. If we look back a few decades,
esteemed societies viewed obesity more as a risk-factor than
disease, and the collective perspective then within the medical
community was aligned accordingly. Since then, although
obesity remains the same thing, our collective perspective
regarding its disease status has changed radically.
The purpose of including this discussion of ‘collective
acceptance’ is not so much to argue for or against obesity
being a disease, but rather a warning for us to understand our
human propensity for collective acceptance of prevailing
beliefs. Such collective acceptance could legitimately be
used to argue for obesity being a disease within our collective
imagination, just as we can all agree on the value of a £5 note.
But that collective acceptance and belief per se counts for
nothing when arguing for whether obesity should be classed
as a disease from a scientific perspective.
3. The scientific argument
A disease is defined as a disordered or incorrectly functioning
organ, part, structure or system of the body. In other words,
pathophysiology justifies disease status. To define obesity as a
disease scientifically therefore, we must identify its underlying
pathophysiology. What is incontrovertible is that obesity (and
its antecedent weight-gain) associates with the development
of multiple diseases that include Type 2 Diabetes Mellitus and
Polycystic Ovary Syndrome for example [4,5]. However, asso-
ciation per se is not equivalent to pathophysiology, and
should not therefore be used solely as a scientific argument
to label obesity with disease status.
In a subgroup of those with obesity, ectopic fat deposition
within liver and muscle ensues, often accompanied by a chronic
inflammatory process within adipose tissue which is thought to
contribute toward insulin resistance and increased risk of cardi-
ovascular events [6]. In this scenario, it could be argued justifi-
ably that obesity should be labelled with disease status. The
disordered structure is the ectopic fat deposition and the over-
abundant and inflamed adipose tissue, each contributing
toward a pathophysiological process. Analogously, hyperten-
sion and dyslipidaemia can also be labelled with disease status
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based on their underlying pathophysiological processes, which
also associate with increased risk of cardiovascular events. In
each of these examples, disease status is justified on the basis
of underlying pathophysiology, and is not dependent upon their
association with (including presence or absence of) cardiovas-
cular events per se.
In another subgroup of those with obesity however,
particularly in younger people or those with more recent
weight-gain, ‘excessive adiposity’ appears to be confined
to a eutopic distribution, with relative absence of ectopic
fat deposition. There may also be relative absence of an
adipogenic inflammatory reaction or even insulin resis-
tance [7]. I would argue that in this subgroup of the
obese, a physiological (and protective) process ensues
whereby expansion of eutopic adipose tissue depots
occurs in response to chronic over-nutrition. While it is
accepted that this physiological process often becomes
pathophysiological over time (as described earlier in this
section), this does not appear inevitable, and misses the
point of this scientific argument: In this important sub-
group (at least transiently), disordered tissues, malfunc-
tioning systems, and pathophysiology do not appear to
exist. It would be difficult to argue that such a physiolo-
gical scenario should be classified as disease status. And
yet, if we are to label obesity with the umbrella terminol-
ogy of disease status then this real-life scenario, by our
current BMI-centric definition, needs to be included.
4. The utilitarian argument
Regardless of its labelling by esteemed societies or its
scientific merits, the question remains whether classifying
obesity as a disease is beneficial for patients. There is a
strong argument that disease-status would provide a man-
date for governments to take obesity more seriously, and
to provide more funding for obesity-related treatment
strategies such as metabolic surgery [3]. This is particularly
apt in the UK, where provision of metabolic surgery for
morbidly obese patients per capita is among the worst in
the whole of Western Europe [8]: a shameful indictment
which is simply unacceptable and cannot be justified.
Furthermore, labelling obesity as a disease may raise its
profile among charitable societies, and promote more
funding for research into the prevention and effective
management of obesity.
Labelling obesity as a disease also has potential to
change societal views. While it is hoped that this would
diminish stigmatization of obesity, evidence to support
the likelihood of this outcome is lacking. Certain diseases
(leprosy and AIDS as examples) have been associated with
much stigmatization [9]. Disease-status per se may there-
fore even have potential to worsen stigmatization of a
condition. A further concern is that labelling obesity as a
disease may reduce motivation of some patients to
improve their lifestyle. Healthcare professionals need to
ensure that their obese patients understand that their
‘disease’ is potentially reversible through effective changes
in eating- and activity-related behaviors.
5. Concluding remarks
There is much stigmatization of obesity within our society.
Many misconceptions about obesity and its causes are
prevalent, and much discrimination exists. Ultimately,
greater funding for obesity-related management strategies
and research is desperately needed. It would seem reason-
able to posit that labelling obesity as a disease would
help to satisfy this unmet need. However, what is really
required is cultural transformation. While labelling obesity
as a disease may form one part of this, it would be naïve
to assume that this alone would change our culture and
society. Cultural transformation will likely be a slow and
gradual process, and will need to include proactivity from
all elements of society. Essential expedients of this process
should include radical changes to the way in which obe-
sity and its causes are portrayed to the public by the
media, government campaigns to promote a clearer
understanding of obesity and its causes within society,
and perhaps most importantly, clear education of our
children on obesity and its causes. If labelling obesity as
a disease will facilitate these changes, then it seems rea-
sonable to assume that this will also result, ultimately in
improved care, experiences and wellbeing of our obese
patients.
The usefulness of obesity as a clinical entity rests pri-
marily on its association with co-morbidities that include
metabolic dysfunction. Although not directly relevant to
the current definition of obesity per se (and perhaps out
of place in this discussion), it is however illuminating to
envision a future scenario in which the definition of obe-
sity is replaced with a concept that is less adipo-centric,
and more cardio-metabolically refined: a new concept to
reflect more accurately future cardio-metabolic risk,
thereby providing greater clinical utility. In addition to
inclusion of measures of fat distribution (such as waist
circumference for visceral fat [2]) into such a new defini-
tion, a measure of cardio-respiratory fitness (CRF) should
also perhaps be incorporated. There is much evidence in
the literature to promote the association of sedentariness
with metabolic dysfunction, and the utility of physical
activity and non-sedentary behavior to improve metabolic
health [10,11]. Although CRF is generally measured on a
maximal stress test, estimation of CRF can also be made
from non-exercise based data [12]. Exploration of future
accurate biomarkers for CRF would seem an important
focus for future research, and would help to establish
CRF as a diagnostically useful entity, rather than one
based primarily within the research sphere.
To conclude, on the basis of the arguments outlined, it
would seem reasonable to support the labelling of obesity
with disease status, on the proviso that we also take the
timely opportunity to re-think, modify and refine our defi-
nition of obesity, to one that more accurately reflects
underlying pathophysiology, and therefore associated car-
diovascular risk. Transforming our definition of obesity to
more accurately reflect disease status will require transfor-
mation away from anachronistic BMI-centricity. Our new
definition should reflect perhaps fat distribution, ectopic
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fat deposition and CRF, whilst also being applicable
clinically.
Einstein said that insanity is when we do the same thing over
and expect different results. If we want improved, rather than the
same dismal results for our obese patients, we have to do things
differently. Modifying our perspective on obesity through labelling
it as a disease could prove one useful expedient for much needed
cultural transformation. We should still leave room though, within
our transformation for healthy debate and consensus on a more
refined disease-centric definition of obesity.
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